GTX Inc (GTXI) 0.71 $GTXI
GTx to Present Results on Enobosarm 9mg in Women with Metastatic Breast Cancer at 2014 San Antonio Breast Cancer Symposium
Business Wire - Mon Dec 08, 7:01AM CST
GTx, Inc. (NASDAQ: GTXI) today announced that the results from its positive proof of concept Phase 2 clinical trial evaluating enobosarm 9mg in post-menopausal women with estrogen receptor (ER) positive and androgen receptor (AR) positive metastatic breast cancer will be featured in a poster presentation at the San Antonio Breast Cancer Symposium taking place December 9 - 13, 2014, in San Antonio, Texas.
GTXI: 0.71 (+0.07)
GTx's USD43.4m private placement closed
M2 - Tue Nov 18, 4:30AM CST
GTx Inc (Nasdaq:GTXI), a biopharmaceutical company, announced on Monday the closing of a private placement of its common stock and warrants to purchase its common stock.
GTXI: 0.71 (+0.07)
GTx Announces Closing of $43.4 Private Placement
Business Wire - Mon Nov 17, 6:00AM CST
GTx, Inc. (NASDAQ: GTXI) today announced that it has closed the previously-announced private placement of its common stock and warrants to purchase its common stock. In the private placement, GTx sold 64,311,112 immediately separable units, comprised of an aggregate of 64,311,112 newly-issued shares of common stock and warrants to purchase up to 64,311,112 additional shares of common stock, for an aggregate purchase price of approximately $43.4 million. Net proceeds to GTx from the private placement are expected to be approximately $42.8 million.
GTXI: 0.71 (+0.07)
GTx Announces Webcast of Corporate Presentation at the Stifel 2014 Healthcare Conference
Business Wire - Wed Nov 12, 6:30AM CST
GTx, Inc. (Nasdaq: GTXI) announced today that management will present a company overview on November 18, 2014, at the Stifel 2014 Healthcare Conference in New York City. The GTx presentation will begin at 3:00 pm EST. A simultaneous webcast of the presentation will be accessible from the GTx website at http://www.gtxinc.com. An archived replay of the presentation will be available on the company website until December 2.
GTXI: 0.71 (+0.07)
GTx's (GTXI) CEO Marc Hanover on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Mon Nov 10, 12:14PM CST
GTXI: 0.71 (+0.07)
GTx net loss improves in Q3
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 10:51AM CST
GTXI: 0.71 (+0.07)
GTx (GTXI) Q3 2014 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Mon Nov 10, 7:55AM CST
GTXI: 0.71 (+0.07)
GTx beats by $0.05
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 6:18AM CST
GTXI: 0.71 (+0.07)
GTx Provides Corporate Update and Reports Third Quarter 2014 Financial Results
Business Wire - Mon Nov 10, 6:15AM CST
--Closing of recently announced private placement will provide cash through 2016 and key breast cancer milestones
GTXI: 0.71 (+0.07)
GTx Announces $43.4 Million Private Placement
Business Wire - Mon Nov 10, 6:01AM CST
GTx, Inc. (NASDAQ: GTXI) today announced that it has entered into a securities purchase agreement for the sale of approximately $43.4 million of its common stock and warrants to purchase common stock in a private placement. The group of accredited investors includes Biotechnology Value Fund, L. P. and other affiliates of BVF Partners L.P., certain existing GTx stockholders and certain members of the GTx management team and board of directors.
GTXI: 0.71 (+0.07)
Notable earnings before Monday’s open
Seeking Alpha - at Seeking Alpha - Sun Nov 09, 4:30PM CST
BID: 38.82 (+0.06), CRIS: 1.18 (+0.03), KWK: 0.30 (-0.02), ARQL: 1.25 (unch), CACQ: 9.03 (-0.28), RIG: 16.47 (-0.55), TRQ: 3.02 (-0.09), MPAA: 31.41 (-1.44), RSPP: 21.03 (-0.03), DF: 18.00 (+0.18), ENTR: 2.48 (-0.02), TA: 10.37 (+0.21), DDD: 30.00 (-0.59), RYN: 26.83 (-0.37), GAS: 51.18 (-1.43), CMCM: 15.65 (+0.29), LIOX: 5.50 (-0.07), WWAV: 33.83 (-0.67), ZINC: 14.49 (-0.41), GTXI: 0.71 (+0.07), GOGO: 15.46 (+0.03), RIGP: 15.27 (-0.20), EVEP: 23.83 (+0.05), SNSS: 2.26 (unch), MGIC: 6.50 (+0.01)
GTx, Inc. To Host Third Quarter 2014 Financial Results Conference Call and Webcast
Business Wire - Mon Nov 03, 4:00PM CST
GTx, Inc. (NASDAQ: GTXI) today announced that it will host a conference call and webcast to provide a corporate update and discuss the Company's third quarter 2014 financial results on Monday, November 10 at 9:00 a.m. Eastern Time. The call and webcast will follow the release of the financial results earlier that day.
GTXI: 0.71 (+0.07)
Hot Stock: GTx, Shares Drop 6.4% (GTXI)
Comtex SmarTrend(R) - Wed Sep 17, 10:37AM CDT
GTx (NASDAQ:GTXI) is one of today's worst performing penny stocks, down 6.4% to $0.74 on 1.4x average daily volume. GTx has traded 302,000 shares thus far today, vs. average volume of 215,000 shares per day. The stock has underperformed the Dow (-6.3% to the Dow's 0.1%) and underperformed the S&P 500 (-6.3% to the S&P's 0.1%) during today's trading.
GTXI: 0.71 (+0.07)
GTx Announces Webcast of Corporate Presentation at the 2014 Wedbush Pacgrow Life Sciences Management Access Conference
Business Wire - Thu Aug 07, 6:30AM CDT
GTx, Inc. (Nasdaq: GTXI) announced today that management will present a company overview on August 13, 2014, at the 2014 Wedbush Pacgrow Life Sciences Management Access Conference in New York City. The GTx presentation will begin at 2:30 pm EST. A simultaneous webcast of the presentation will be accessible from the GTx website at http://www.gtxinc.com. An archived replay of the presentation will be available on the company website until August 27.
GTXI: 0.71 (+0.07)
Investors look to Lighten Up on Shares of GTx, Shares Down 7.8% (GTXI)
Comtex SmarTrend(R) - Wed Aug 06, 12:42PM CDT
GTx (NASDAQ:GTXI) is one of today's worst performing low-priced stocks, down 7.8% to $1.06 on 1.1x average daily volume. GTx has traded 448,000 shares thus far today, vs. average volume of 419,000 shares per day. The stock has underperformed the Dow (-7.8% to the Dow's 0.2%) and underperformed the S&P 500 (-7.8% to the S&P's 0.2%) during today's trading.
GTXI: 0.71 (+0.07)
GTx Provides Corporate Update and Reports Second Quarter 2014 Financial Results
Business Wire - Tue Aug 05, 6:00AM CDT
GTx, Inc. (Nasdaq: GTXI) today reported financial results for the quarter and six months ended June 30, 2014. The Company also highlighted clinical development progress with enobosarm, an oral selective androgen receptor modulator, as well as progress with GTx-758, its oral nonsteroidal selective estrogen receptor alpha agonist, being studied for secondary hormonal therapy in men with castration-resistant prostate cancer.
GTXI: 0.71 (+0.07)
GTx, Inc. to Report Second Quarter 2014 Financial Results on August 5, 2014
Business Wire - Tue Jul 22, 6:30AM CDT
GTx, Inc. (NASDAQ: GTXI) today announced that the date for its second quarter 2014 financial results press release will be Tuesday, August 5, 2014, prior to the opening of the U.S. stock markets. Similar to the previous quarter, the Company is not planning to host a conference call or webcast on that date, but will continue to provide periodic updates on clinical trial results and other material company developments as appropriate throughout the remainder of the year.
GTXI: 0.71 (+0.07)
4 Biotech Stocks Under $10 to Watch for Breakout Trades
at The Street - Wed Jul 02, 7:18AM CDT
These under-$10 biotech stocks are within range of triggering breakout trades.
GTXI: 0.71 (+0.07), RXDX: 6.75 (-0.18), XOMA: 4.68 (-0.02), MEIP: 4.20 (unch)
Corneal Neovascularization - Pipeline Review, H1 2014
M2 - Thu Jun 12, 2:34AM CDT
Research and Markets (http://www.researchandmarkets.com/research/lld3cs/corneal) has announced the addition of the "Corneal Neovascularization - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Corneal Neovascularization, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Corneal Neovascularization and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Corneal Neovascularization - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Corneal Neovascularization and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Corneal Neovascularization products under development by companies and universities/research institutes based on information derived from company and industry-specific sources Companies Mentioned: - F. Hoffmann-La Roche Ltd. - GTx, Inc. - Sirnaomics, Inc. - Amakem NV For more information visit http://www.researchandmarkets.com/research/lld3cs/corneal
GTXI: 0.71 (+0.07)
GTx Provides Corporate Update and Reports 2013 Financial Results
Business Wire - Tue Mar 04, 6:00AM CST
GTx, Inc. (Nasdaq: GTXI) today provided a Company update and reported financial results for the fourth quarter and full year 2013.
GTXI: 0.71 (+0.07)
GTx to Present Results on Enobosarm 9mg in Women with Metastatic Breast Cancer at 2014 San Antonio Breast Cancer Symposium
Business Wire - Mon Dec 08, 7:01AM CST
GTx, Inc. (NASDAQ: GTXI) today announced that the results from its positive proof of concept Phase 2 clinical trial evaluating enobosarm 9mg in post-menopausal women with estrogen receptor (ER) positive and androgen receptor (AR) positive metastatic breast cancer will be featured in a poster presentation at the San Antonio Breast Cancer Symposium taking place December 9 - 13, 2014, in San Antonio, Texas.
GTXI: 0.71 (+0.07)
GTx's USD43.4m private placement closed
M2 - Tue Nov 18, 4:30AM CST
GTx Inc (Nasdaq:GTXI), a biopharmaceutical company, announced on Monday the closing of a private placement of its common stock and warrants to purchase its common stock.
GTXI: 0.71 (+0.07)
GTx Announces Closing of $43.4 Private Placement
Business Wire - Mon Nov 17, 6:00AM CST
GTx, Inc. (NASDAQ: GTXI) today announced that it has closed the previously-announced private placement of its common stock and warrants to purchase its common stock. In the private placement, GTx sold 64,311,112 immediately separable units, comprised of an aggregate of 64,311,112 newly-issued shares of common stock and warrants to purchase up to 64,311,112 additional shares of common stock, for an aggregate purchase price of approximately $43.4 million. Net proceeds to GTx from the private placement are expected to be approximately $42.8 million.
GTXI: 0.71 (+0.07)
GTx Announces Webcast of Corporate Presentation at the Stifel 2014 Healthcare Conference
Business Wire - Wed Nov 12, 6:30AM CST
GTx, Inc. (Nasdaq: GTXI) announced today that management will present a company overview on November 18, 2014, at the Stifel 2014 Healthcare Conference in New York City. The GTx presentation will begin at 3:00 pm EST. A simultaneous webcast of the presentation will be accessible from the GTx website at http://www.gtxinc.com. An archived replay of the presentation will be available on the company website until December 2.
GTXI: 0.71 (+0.07)
GTx's (GTXI) CEO Marc Hanover on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Mon Nov 10, 12:14PM CST
GTXI: 0.71 (+0.07)
GTx net loss improves in Q3
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 10:51AM CST
GTXI: 0.71 (+0.07)
GTx (GTXI) Q3 2014 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Mon Nov 10, 7:55AM CST
GTXI: 0.71 (+0.07)
GTx beats by $0.05
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 6:18AM CST
GTXI: 0.71 (+0.07)
GTx Provides Corporate Update and Reports Third Quarter 2014 Financial Results
Business Wire - Mon Nov 10, 6:15AM CST
--Closing of recently announced private placement will provide cash through 2016 and key breast cancer milestones
GTXI: 0.71 (+0.07)
GTx Announces $43.4 Million Private Placement
Business Wire - Mon Nov 10, 6:01AM CST
GTx, Inc. (NASDAQ: GTXI) today announced that it has entered into a securities purchase agreement for the sale of approximately $43.4 million of its common stock and warrants to purchase common stock in a private placement. The group of accredited investors includes Biotechnology Value Fund, L. P. and other affiliates of BVF Partners L.P., certain existing GTx stockholders and certain members of the GTx management team and board of directors.
GTXI: 0.71 (+0.07)
Notable earnings before Monday’s open
Seeking Alpha - at Seeking Alpha - Sun Nov 09, 4:30PM CST
BID: 38.82 (+0.06), CRIS: 1.18 (+0.03), KWK: 0.30 (-0.02), ARQL: 1.25 (unch), CACQ: 9.03 (-0.28), RIG: 16.47 (-0.55), TRQ: 3.02 (-0.09), MPAA: 31.41 (-1.44), RSPP: 21.03 (-0.03), DF: 18.00 (+0.18), ENTR: 2.48 (-0.02), TA: 10.37 (+0.21), DDD: 30.00 (-0.59), RYN: 26.83 (-0.37), GAS: 51.18 (-1.43), CMCM: 15.65 (+0.29), LIOX: 5.50 (-0.07), WWAV: 33.83 (-0.67), ZINC: 14.49 (-0.41), GTXI: 0.71 (+0.07), GOGO: 15.46 (+0.03), RIGP: 15.27 (-0.20), EVEP: 23.83 (+0.05), SNSS: 2.26 (unch), MGIC: 6.50 (+0.01)
GTx, Inc. To Host Third Quarter 2014 Financial Results Conference Call and Webcast
Business Wire - Mon Nov 03, 4:00PM CST
GTx, Inc. (NASDAQ: GTXI) today announced that it will host a conference call and webcast to provide a corporate update and discuss the Company's third quarter 2014 financial results on Monday, November 10 at 9:00 a.m. Eastern Time. The call and webcast will follow the release of the financial results earlier that day.
GTXI: 0.71 (+0.07)
Hot Stock: GTx, Shares Drop 6.4% (GTXI)
Comtex SmarTrend(R) - Wed Sep 17, 10:37AM CDT
GTx (NASDAQ:GTXI) is one of today's worst performing penny stocks, down 6.4% to $0.74 on 1.4x average daily volume. GTx has traded 302,000 shares thus far today, vs. average volume of 215,000 shares per day. The stock has underperformed the Dow (-6.3% to the Dow's 0.1%) and underperformed the S&P 500 (-6.3% to the S&P's 0.1%) during today's trading.
GTXI: 0.71 (+0.07)
GTx Announces Webcast of Corporate Presentation at the 2014 Wedbush Pacgrow Life Sciences Management Access Conference
Business Wire - Thu Aug 07, 6:30AM CDT
GTx, Inc. (Nasdaq: GTXI) announced today that management will present a company overview on August 13, 2014, at the 2014 Wedbush Pacgrow Life Sciences Management Access Conference in New York City. The GTx presentation will begin at 2:30 pm EST. A simultaneous webcast of the presentation will be accessible from the GTx website at http://www.gtxinc.com. An archived replay of the presentation will be available on the company website until August 27.
GTXI: 0.71 (+0.07)
Investors look to Lighten Up on Shares of GTx, Shares Down 7.8% (GTXI)
Comtex SmarTrend(R) - Wed Aug 06, 12:42PM CDT
GTx (NASDAQ:GTXI) is one of today's worst performing low-priced stocks, down 7.8% to $1.06 on 1.1x average daily volume. GTx has traded 448,000 shares thus far today, vs. average volume of 419,000 shares per day. The stock has underperformed the Dow (-7.8% to the Dow's 0.2%) and underperformed the S&P 500 (-7.8% to the S&P's 0.2%) during today's trading.
GTXI: 0.71 (+0.07)
GTx Provides Corporate Update and Reports Second Quarter 2014 Financial Results
Business Wire - Tue Aug 05, 6:00AM CDT
GTx, Inc. (Nasdaq: GTXI) today reported financial results for the quarter and six months ended June 30, 2014. The Company also highlighted clinical development progress with enobosarm, an oral selective androgen receptor modulator, as well as progress with GTx-758, its oral nonsteroidal selective estrogen receptor alpha agonist, being studied for secondary hormonal therapy in men with castration-resistant prostate cancer.
GTXI: 0.71 (+0.07)
GTx, Inc. to Report Second Quarter 2014 Financial Results on August 5, 2014
Business Wire - Tue Jul 22, 6:30AM CDT
GTx, Inc. (NASDAQ: GTXI) today announced that the date for its second quarter 2014 financial results press release will be Tuesday, August 5, 2014, prior to the opening of the U.S. stock markets. Similar to the previous quarter, the Company is not planning to host a conference call or webcast on that date, but will continue to provide periodic updates on clinical trial results and other material company developments as appropriate throughout the remainder of the year.
GTXI: 0.71 (+0.07)
4 Biotech Stocks Under $10 to Watch for Breakout Trades
at The Street - Wed Jul 02, 7:18AM CDT
These under-$10 biotech stocks are within range of triggering breakout trades.
GTXI: 0.71 (+0.07), RXDX: 6.75 (-0.18), XOMA: 4.68 (-0.02), MEIP: 4.20 (unch)
Corneal Neovascularization - Pipeline Review, H1 2014
M2 - Thu Jun 12, 2:34AM CDT
Research and Markets (http://www.researchandmarkets.com/research/lld3cs/corneal) has announced the addition of the "Corneal Neovascularization - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Corneal Neovascularization, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Corneal Neovascularization and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Corneal Neovascularization - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Corneal Neovascularization and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Corneal Neovascularization products under development by companies and universities/research institutes based on information derived from company and industry-specific sources Companies Mentioned: - F. Hoffmann-La Roche Ltd. - GTx, Inc. - Sirnaomics, Inc. - Amakem NV For more information visit http://www.researchandmarkets.com/research/lld3cs/corneal
GTXI: 0.71 (+0.07)
GTx Provides Corporate Update and Reports 2013 Financial Results
Business Wire - Tue Mar 04, 6:00AM CST
GTx, Inc. (Nasdaq: GTXI) today provided a Company update and reported financial results for the fourth quarter and full year 2013.
GTXI: 0.71 (+0.07)
